Synaptogenix Inc SNPX

NAS: SNPX | ISIN: US87167T2015   7/05/2024
4,680 USD (-0,64%)
(-0,64%)   7/05/2024
Grafiek Synaptogenix Inc Grafiek Synaptogenix Inc

Synaptogenix Inc in het nieuws

7 mei 2024 · Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery · Persbericht

24 april 2024 · Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing · Persbericht

9 april 2024 · Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics · Persbericht

3 april 2024 · Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing · Persbericht

19 december 2023 · Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders · Persbericht

6 december 2023 · Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's · Persbericht

2 november 2023 · Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology · Persbericht

26 september 2023 · Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease · Persbericht

7 september 2023 · Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study · Persbericht

19 juli 2023 · Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis · Persbericht

Profiel Synaptogenix Inc

synaptogenix is een biofarmaceutisch bedrijf in een klinische fase dat van oudsher werkt aan de ontwikkeling van nieuwe therapieën voor neurodegeneratieve ziekten.

Werknemers: 5

Aandelen Synaptogenix Inc

Beurswaarde: 127,80 miljoen USD

Effecten: 27,13 miljoen

Mijn selecties